News

AgroSpheres and BASF Announce Major Strategic Partnership

AgroSpheres, a biotechnology leader in sustainable crop protection and crop health, and BASF, a global leader in agricultural solutions, are excited to announce their strategic partnership on a category defining novel bioinsecticide. This collaboration marks a significant step forward in sustainable agriculture solutions aimed at enhancing crop protection.

The companies are working together to develop biological crop protection products leveraging AgroSpheres AgriCell-powered biomolecules. Both companies are encouraged by the levels of efficacy that have been demonstrated at low dose rates to control key agricultural lepidopteran pests. Both companies are committed to working together to develop innovative and sustainable crop protection products that will increase the choices available to farmers to manage pests and support optimal productivity.

Payam Pourtaheri, CoFounder and CEO of AgroSpheres, stated, “Our partnership with BASF exemplifies the synergy that can be achieved when innovative biotech meets extensive agricultural expertise. The results of our bioinsecticide development are extremely promising, and we are eager to continue our work together to bring effective solutions to farmers worldwide.”

Ameer Shakeel, CoFounder and CTO of AgroSpheres, added, “This collaboration is a testament to our team’s ability to develop novel biomolecules, amplify them with the AgriCell and forge strategic partnerships to reach farmers around the world. We are proud to partner with BASF and are excited about the potential impact of our partnership.”

Both companies are committed to furthering their research and development efforts, with plans to accelerate the development of this product line and launch a pipeline powered by the AgriCell.

Stephanie Jensen, Vice President, Crop System Rice and Portfolio Solutions Insecticides and Seed Treatment, BASF Agricultural Solutions, concluded, “We are incredibly encouraged by the results we’ve achieved thus far and by the potential impact for our customers from this innovative technology. Moving forward, our focus remains on delivering a bioinsecticide that adds genuine value for farmers, promoting higher yields and healthier crops.”

Stefan Tresch, Head of New Technologies & BioSolutions at BASF Agricultural Solutions, remarked, “BASF is dedicated to developing innovative solutions that provide added benefit to our agricultural customers, and we believe in the unique value represented by the AgriCell platform. AgroSpheres has showcased some of the most promising biomolecules we’ve encountered. Our collaboration with AgroSpheres is a testament to the power of partnerships in driving innovation.”

Both AgroSpheres and BASF are dedicated to fostering a sustainable agricultural ecosystem, and this partnership is a crucial step in that journey.

 

Learn more here.

Recent News

06/11/2026

Adial Pharmaceuticals Announces Acquisition of Azora Therapeutics and up to $64 Million Financing

Adial Pharmaceuticals, Inc. (Nasdaq: ADIL) (“Adial” or the “Company”) today announced that it has acquired Azora Therapeutics, Inc. (“Azora”), a biopharmaceutical company developing treatments for serious inflammatory diseases. The acquisition brings Azora’s lead asset AT177, a proprietary colon‑targeted aryl hydrocarbon receptor (AhR) agonist designed to enable localized activation with limited systemic exposure, into Adial’s pipeline.

06/11/2026

Luna Labs Launches 3 Waves Venture Spinout to Commercialize Advanced Vestibular Stimulation Technology

Luna Labs today announced the launch of 3 Waves, Inc. (“3Waves”), a dual-use spinout company that was established to commercialize advanced virtual and mixed reality technologies for defense, commercial simulation, and medical applications. As part of the spinout, 3Waves and Mayo Clinic executed an exclusive license to support the development of next-generation vestibular stimulation systems

06/02/2026

TearSolutions Receives FDA Orphan Drug and Fast Track Designations for Lacripep® in Neurotrophic Keratitis and Initiates Phase 2 Clinical Trial with First Patients Dosed

TearSolutions, Inc. (“TearSolutions”), a clinical-stage biotechnology company developing novel ophthalmic therapeutics, today announced receiving Food and Drug Administration (FDA) Orphan Drug (ODD) and Fast Track Designations for Lacripep in Neurotrophic Keratitis (NK) and initiating a Phase 2 clinical trial with first patients dosed. The FDA’s ODD provides incentives, including tax credits for clinical testing and